CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual Meeting

Due to the concern of fratricide, clinical development of CAR T cells for the therapy of T cell malignancies lags behind that for B cell malignancies. Attempts are being made to revise T cell biomarkers so that the re-engineered CAR T cells can target T cell malignancies. CD3 and CD7 are the two pan...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Qiusha, Zhang, Xiao-hui, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985840/
https://www.ncbi.nlm.nih.gov/pubmed/36871011
http://dx.doi.org/10.1186/s13045-023-01406-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985840/
https://www.ncbi.nlm.nih.gov/pubmed/36871011
http://dx.doi.org/10.1186/s13045-023-01406-8

Ejemplares similares